



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

3 April 2020 (#19)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

**Tygerberg Campus:** [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • **Stellenbosch Campus** [lizek@sun.ac.za](mailto:lizek@sun.ac.za)

## Important Notice

- **[New NIAID R01 Opportunity allows up to Seven-Year Investigator-Initiated Clinical Trials](#)**. NIAID has a suite of funding opportunity announcements (FOAs) designed to support [Investigator-Initiated Clinical Trials](#) (IICTs). NIAID identified a limitation in our toolkit—the inability to provide longer project periods for certain studies—which we’ve addressed by participating in [Investigator-Initiated Extended Clinical Trial \(R01, Clinical Trial Required\)](#). NIAID uses two FOAs to support IICTs for five-year project periods; an R01 for low-risk projects and a U01 for high-risk projects. s with other IICT FOAs, NIAID recommends potential applicants to complete a prior consultation with NIAID staff at least 10 weeks before the application due date. The consultation affords us a chance to ensure that you are applying to the FOA that best matches your proposed research project. Learn more at [Requesting Prior Consultation: Clinical Trial Applications and Planning Grants](#).
- **[Requesting Assignments From](#)** the Center for Scientific Review. By using the optional [PHS Assignment Request Form](#), you can convey the following to Division of Receipt Referral. Keep in mind that you do not need to fill in all of the form’s fields or sections.

### 1. Innovation for HIV Vaccine Discovery (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-20-158](#)

**Type:** R01

**Application Due Date:** July 28, 2020; July 28, 2021; July 28, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support high risk, high impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high risk, high impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated “Go/No-Go” criteria by the end of Year 2.

**Budget:** Application budgets are limited to \$350,000 per year in direct costs. Applicants may request up to an additional \$150,000 per year in direct costs in any year when research in nonhuman primate or humanized mice models is proposed and justified. Project duration is no more than four years. Applicants should submit a 4 year project period, and are required to identify Go/No-Go decision criteria to be achieved for the Year 2 progress report to allow continued funding for years 3 and 4. Achievement of the stated goal(s) (Go) will enable continuation of the R01 for years 3 and 4, while failure to achieve the stated goal(s) (No-Go) will result in negotiation of a reduced budget for Year 3 and Year 4.

### 2. Advancing Vaccine Science to Improve Tuberculosis Treatment Outcomes for People Living With or Without HIV (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-20-010](#)

**Type:** R01

**Application Due Date:** July 28, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement is to invite applications for innovative clinical, and preclinical/translational research to develop therapeutic vaccine strategies to improve treatment outcomes of active tuberculosis (TB) in the presence or absence of HIV co-infection.

**Budget:** NIAID intends to commit \$4 million in FY 2021 to fund 2-3 awards. Application budgets are limited to \$800,000 in direct costs per year, but also need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 3. Harnessing Natural Killer (NK) Cells to Prevent, Control, or Eradicate HIV (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-20-016](#)

**Type:** R01

**Application Due Date:** July 28, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) will support basic, translational, and clinical research to improve the understanding of the effector or immunoregulatory potentials of NK cells for HIV prevention, control and/or eradication.

**Budget:** NIAID and partner components intend to commit an estimated total of \$3,250,000 in FY21 to fund 4-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

### 4. Engineering Immunity to HIV-1 Through Next Generation Vaccines (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-20-015](#)

**Type:** R61/R33

**Application Due Date:** July 28, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The objective of this Funding Opportunity Announcement (FOA) is to pair Bioengineers and Immunologists to leverage emerging innovative knowledge in physical and computational sciences for the design and development of an HIV-1 vaccine.

**Budget:** NIAID intends to commit \$5,000,000 in FY 2021 to fund 4-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this FOA cannot exceed five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

### 5. Tuberculosis Research Units (U19 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-20-020](#)

**Type:** U19

**Application Due Date:** September 28, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this FOA is to support the establishment of multidisciplinary Tuberculosis (TB) Research Units (TBRUs) that will operate as a collaborative network to improve understanding of Mycobacterium tuberculosis (Mtb)-host interactions through characterization of bacterial and host determinants that are relevant during stages of infection and disease, and analyses of bacterial and host heterogeneity on disease outcomes.

**Budget:** NIAID intends to commit \$10 million in FY 2020 to fund 2-3 awards. Applicants may propose a recommended budget of up to \$1.8 million per year in direct costs. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 6. Long Acting Treatments for HIV and HIV-Associated Co-Infections (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-20-024](#)

**Type:** R61/R33

**Application Due Date:** July 28, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis (TB) and viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products.

**Budget:** NIAID intends to commit \$3.5M in FY 2021 to fund 3-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this FOA is five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105